Nenad Sarapa
Research Subjects
Research Interests
Nenad Sarapa has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
D J Nickens
Biostatistics, Pfizer Global R&D San Diego California USA
1 shared publicationM A Amantea
Clinical Pharmacology, Pfizer Global R&D San Diego California USA
1 shared publicationR R Reynolds
Clinical Pharmacology, Pfizer Global R&D San Diego California USA
1 shared publicationS R Raber
Clinical Pharmacology, Pfizer Global R&D San Diego California USA
1 shared publication
Latest Publications
- 18 September 2007
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 6 (5) , 595-607
Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG warehouse
The FDA mandates that digital electrocardiograms (ECGs) from 'thorough' QTc trials be submitted into the ECG Warehouse in Health Level 7 extended markup language format with annotated onset and offset points of waveforms. The FDA did not disclose the exact Warehouse metrics and minimal acceptable quality standards. The author describes the Warehouse scoring algorithms and metrics used by FDA, points out ways to improve FDA review and suggests Warehouse benefits for pharmaceutical sponsors. The Warehouse ranks individual ECGs according to their score for each quality metric and produces histogram distributions with Warehouse-specific thresholds that identify ECGs of questionable quality. Automatic Warehouse algorithms assess the quality of QT annotation and duration of manual QT measurement by the central ECG laboratory.
- 18 September 2007
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 6 (5) , 595-607
Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG warehouse
The FDA mandates that digital electrocardiograms (ECGs) from 'thorough' QTc trials be submitted into the ECG Warehouse in Health Level 7 extended markup language format with annotated onset and offset points of waveforms. The FDA did not disclose the exact Warehouse metrics and minimal acceptable quality standards. The author describes the Warehouse scoring algorithms and metrics used by FDA, points out ways to improve FDA review and suggests Warehouse benefits for pharmaceutical sponsors. The Warehouse ranks individual ECGs according to their score for each quality metric and produces histogram distributions with Warehouse-specific thresholds that identify ECGs of questionable quality. Automatic Warehouse algorithms assess the quality of QT annotation and duration of manual QT measurement by the central ECG laboratory.
- 20 June 2007
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 83 (1) , 153-159
Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc Studies
To assess the QTc prolongation by ritonavir (RTV) 100 mg and explore its potential use as CYP3A inhibitor in thorough QTc (TQT) studies. Randomized, crossover study of single-dose RTV 100 mg, placebo, and moxifloxacin (MFLX) 400 mg in 65 healthy subjects with serial triplicate electrocardiograms obtained for 12 h post-dose. Largest mean placebo-adjusted QTcF increase from baseline (90% confidence interval (CI)) for RTV 100 mg was noninferior to placebo (0.16 ms (-1.38, 1.69)). Study sensitivity was validated by detecting the largest mean placebo-adjusted QTcF increase from baseline (90% CI) for MFLX of 8.31 ms (6.44, 10.18). A single dose of RTV 100 mg does not cause QTc prolongation in healthy subjects. Based on the potent CYP3A4 inhibition, lack of QTc effect and better safety profile, RTV 100 mg could replace ketoconazole as the CYP3A4 inhibitor in TQT studies.
- 20 June 2007
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 83 (1) , 153-159
Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc Studies
To assess the QTc prolongation by ritonavir (RTV) 100 mg and explore its potential use as CYP3A inhibitor in thorough QTc (TQT) studies. Randomized, crossover study of single-dose RTV 100 mg, placebo, and moxifloxacin (MFLX) 400 mg in 65 healthy subjects with serial triplicate electrocardiograms obtained for 12 h post-dose. Largest mean placebo-adjusted QTcF increase from baseline (90% confidence interval (CI)) for RTV 100 mg was noninferior to placebo (0.16 ms (-1.38, 1.69)). Study sensitivity was validated by detecting the largest mean placebo-adjusted QTcF increase from baseline (90% CI) for MFLX of 8.31 ms (6.44, 10.18). A single dose of RTV 100 mg does not cause QTc prolongation in healthy subjects. Based on the potent CYP3A4 inhibition, lack of QTc effect and better safety profile, RTV 100 mg could replace ketoconazole as the CYP3A4 inhibitor in TQT studies.